Zoetis
Zoetis Inc. (NYSE: ZTS) discovers, develops, manufactures and commercializes animal medicines, vaccines, diagnostics, services, biodevices, genetic tests and precision animal health products. Its customers include veterinarians, pet owners, livestock producers and veterinary distributors, serving companion animals and… From the company’s description.
In fiscal 2025, Zoetis reported revenue of $9.47B, up 2.3% from fiscal 2024, and net income of $2.67B. Its operating margin was 37.5%, and operations generated $2.90B in cash. Over the twelve months to Jun 30, 2026, revenue was $9.52B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Zoetis does
In the company’s own words
Zoetis Inc. (NYSE: ZTS) discovers, develops, manufactures and commercializes animal medicines, vaccines, diagnostics, services, biodevices, genetic tests and precision animal health products. Its customers include veterinarians, pet owners, livestock producers and veterinary distributors, serving companion animals and livestock across eight core species. The portfolio spans parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals and animal health diagnostics, with brands including Simparica, Apoquel, Cytopoint, Librela and Vetscan. Zoetis reports two operating segments: the United States, which generated $5.097 billion, or 54% of revenue, in 2025, and International, which generated $4.254 billion, or 45%; contract manufacturing and human health products accounted for the remainder. Companion animal products represented about 70% of 2025 revenue and livestock products about 29%. The company generated $9.4 billion in total revenue in 2025 and sells products in more than 100 countries. Incorporated in 2012, Zoetis was previously a business unit of Pfizer. Its website is www.zoetis.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PARSIPPANY, NJ
- Fiscal year end
- December
- CIK
- 1555280
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Zoetis — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Zoetis · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Zoetis’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Zoetis’s bonds, as funds hold them
Funds report holding 11 issues of Zoetis’s debt, $1.35B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.48%, maturing 2027 to 2050.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Zoetis and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Zoetis's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Zoetis's last four quarterly filings that the numbers alone won't show?”